Resource Center

CMS Enforcement of Average Sales Price (ASP) Submissions for all Medicare Part B Eligible Pharmaceuticals and BiopharmaceuticalsRecently, CMS has been sending letters to pharma and biopharma manufacturers (with and without MDRP agreements) indicating that they believe...

Update – 2023 Best Price & Accumulator Adjustment Program Ruling2023 was shaping up to be a year of challenging decisions for manufacturers and restricted access to critical pharmaceuticals for patients. The 2023 implementation of the proposed CMS Medicaid Best...

Inflation Reduction Act Likely to Have a Negative Financial Impact On Many Drug ManufacturersOn August 16, 2022, the Inflation Reduction Act of 2022 was signed into law with provisions aimed at lowering drug, health care and energy costs for consumers in the United...

Branded Prescription Drug Fee – Payment Deadline ApproachingFriendly reminder to all of our industry colleagues! The final Branded Prescription Drug Fee invoices should be mailed soon. No later than August 31st of each year, the IRS mails the final fee calculation to...

Part I – Unwinding Medicaid Continuous Enrollment May 2022After a slight decline from 2017 to 2019, Medicaid enrollment rose sharply throughout the pandemic. Historically, Medicaid enrollment tracks with unemployment rates. When rates rise, enrollment increases....

Reasons to prepare now for the 2024 Medicaid rebate cap removalDoes it feel like proposed Medicaid rule changes are too far in the future to think about? Or the proposed changes appear so dramatic that it seems unlikely to pass into law, so there’s little need to...

2023 Final Rule Updates for Drug Manufacturers Originally published March 2022; updated May 2022UPDATE May 18, 2022 2023 was shaping up to be a year of challenging decisions for manufacturers and restricted access to critical pharmaceuticals for patients. The 2023...